Date
Press Releases
2022-12-22
Resignation of Chief Medical Officer
2022-11-01
Regencell Bioscience Holdings Limited Files Its 2022 Annual Report (Form 20-F)
2022-09-12
Regencell Bioscience’s Standardized Formulae Are Shown to Reduce ADHD abd ASD Symptoms in the Interim Results of its Second Efficacy Trial
2022-06-02
Regencell Bioscience Holdings Limited Announces First Half 2022 Management Financial Results
2022-05-18
Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19™ in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period
2022-05-16
Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO
2022-02-16
Regencell Bioscience Announces Investigational Liquid-Formula RGC-COV19™ Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy Trial
2021-12-13
Regencell Bioscience Holdings Limited Appoints Dr. William Wing-Yan Lo, JP to its Board of Directors
2021-11-22
Regencell Bioscience Holdings Limited Announces Over $1 Million Ordinary Share Purchase by CEO
Regencell Bioscience Holdings Limited Included in the MSCI World Micro Cap Index
2021-09-02
Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment
2021-08-20
Regencell Bioscience Holdings Limited Announces Partial Exercise of Underwriter’s Over-Allotment Option
2021-08-05
Regencell Bioscience Holdings Limited Releases CEO Letter to Shareholders
2021-07-20
Regencell Bioscience Holdings Limited Announces Closing of Initial Public Offering
Regencell Bioscience Holdings Limited Announces Pricing of Approximately $21.9 Million Initial Public Offering
